FDA Clears Rapid Medical’s Drivewire 35 Steerable Guidewire for Stroke and Other Intravascular Procedures

July 21, 2026—Rapid Medical announced FDA clearance of its Drivewire 35, which is a steerable 0.035-inch guidewire designed to help physicians reach the treatment site quickly and precisely during stroke and other intravascular procedures.

Imperative Care Launches Ikon 24 Pro Guidewire for Stroke Procedures

July 20, 2026—Imperative Care announced the launch of the Ikon 24 Pro guidewire.

Stereotaxis Completes Acquisition of Robocath

July 13, 2026—Stereotaxis announced that it has completed its previously announced acquisition of Robocath, a Rouen, France-based developer of robotic technologies for interventional cardiology and neurointerventions.

Penumbra Begins FORWARD Study of Red Perfusion Catheter Portfolio in Distal Acute Ischemic Stroke Management

July 7, 2026—Penumbra, Inc. announced the initiation of its FORWARD study, which will collect safety and efficacy data on mechanical thrombectomy in the management of acute ischemic stroke with distal occlusions.

Penumbra’s Red 72 Silver Label Reperfusion Catheters Receive CE Mark Approval for Acute Ischemic Stroke

June 30, 2026—Penumbra Inc. announced it has received CE Mark approval for its Red 72 Silver Label and Red 72 Silver Label with SendIt technology.

STRIDE Pivotal Trial of CereVasc’s eShunt System Completes Enrollment

June 24, 2026—CereVasc, Inc. announced it has completed patient enrollment in the STRIDE pivotal trial, which is evaluating the company’s investigational eShunt system in patients with normal pressure hydrocephalus (NPH).

Route 92’s Neurovascular Portfolio Approved in Canada

June 22, 2026—Route 92 Medical, Inc. announced that the first commercial cases in Canada were performed with the company’s neurovascular devices.

ThruFlo Secures Funding to Advance Development of Its Flow Diverter for Bifurcation Aneurysms

June 16, 2026—ThruFlo Endovascular, Inc., a neuroendovascular medical device company, announced the completion of seed funding to accelerate development of its bifurcated flow diverter platform.

Penumbra’s Thunderbolt CAVT Platform for Stroke Gains CE Mark Approval 

June 15, 2026—Penumbra, Inc. announced CE Mark approval for the company’s Thunderbolt computer-assisted vacuum thrombectomy (CAVT) platform to treat acute ischemic stroke.

Medtronic Completes Acquisition of Scientia Vascular

June 12, 2026—Medtronic announced it has completed its acquisition of Scientia Vascular, a privately held developer of access products for the treatment of complex neurovascular conditions.

Penumbra’s Thunderbolt CAVT Platform Cleared by FDA for Stroke Treatment

June 11, 2026—Penumbra, Inc. announced it has received FDA clearance for the Thunderbolt computer-assisted vacuum thrombectomy (CAVT) platform for the treatment of acute ischemic stroke.

CereVasc Financing Will Advance eShunt System to Treat Normal Pressure Hydrocephalus

June 5, 2026—CereVasc, Inc. announced it has completed the initial closing of an $85 million Series C financing.

Mentice and Siemens Partner on Neurovascular Treatment Planning

June 2, 2026—Mentice AB announced a comarketing agreement with Siemens Healthineers to allow clinicians access to the Mentice Ankyras clinical decision-support software for intracranial aneurysms with the Siemens Healthineers Artis Icono angiography systems.

J&J Receives CE Mark Approvals for Cereglide Aspiration Devices for Stroke Treatment

June 2, 2026—Johnson & Johnson (J&J) announced it has received CE Mark approvals for its Cereglide 42 and Cereglide 57 aspiration catheters.

Cercare Receives FDA Clearance for CBCT Perfusion, Collaborates With Siemens on Acute Stroke Care

May 29, 2026—Cercare Medical, a developer of neuroimaging software, announced FDA 510(k) clearance for the company’s Cone-Beam CT Perfusion (CBCT-P) solution, which is intended to enable qualitative perfusion assessment directly from cone-beam CT data acquired during neurointerventional procedures.

Terumo Neuro’s HydroCoil Embolic System to Treat Ruptured Intracranial Aneurysms Studied in RAGE

May 27, 2026—Terumo Neuro, a wholly owned subsidiary of Terumo Corporation, announced the publication of results from the RAGE study of ruptured aneurysms treated with hydrogel coils.

RADIANT Pivotal Trial Approved for Arsenal’s NeoCast Liquid Embolic for Chronic Subdural Hematoma

May 26, 2026—Arsenal Medical announced that the FDA granted investigational device exemption approval for the RADIANT pivotal trial.

FDA Approves Reduced Shake Time for Medtronic’s Onyx 18 and Onyx 34

May 19, 2026—Medtronic Neurovascular announced that its Onyx Liquid Embolic System (LES), Onyx 18 and Onyx 34, received FDA approval for a shake time of at least 1 minute with the same product performance.

IDE Approved for Pivotal Study of InspireMD’s SwitchGuard Neuro Protection System

May 14, 2026—InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke, announced that the FDA has approved the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS III pivotal study.

DISTALS Trial Data Presented for Rapid Medical Tigertriever 13 in DMVO Stroke

May 7, 2026—Rapid Medical announced full results from the DISTALS randomized clinical trial demonstrating that the company’s Tigertriever 13 thrombectomy system can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke.